BRIEF-Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202

Context Therapeutics, Inc.
BioAtla, Inc.

Context Therapeutics, Inc.

CNTX

0.00

BioAtla, Inc.

BCAB

0.00

May 18 (Reuters) - Context Therapeutics CNTX.O:

  • CONTEXT THERAPEUTICS ENTERS INTO LICENSE AGREEMENT AMENDMENT WITH BIOATLA FOR CT-202

  • CONTEXT THERAPEUTICS - ANNOUNCES BUYOUT OF CT-202 FUTURE MILESTONES AND ROYALTIES

  • CONTEXT THERAPEUTICS: AMENDMENT REMOVES ALL FUTURE MILESTONE AND ROYALTY OBLIGATIONS OWED BY COMPANY FOR CT-202

  • CONTEXT THERAPEUTICS - TO PAY $4.5 MILLION UPFRONT AND $2.0 MILLION BY AUG 1, 2026 FOR CT-202 LICENSE

Source text: ID:nGNX9Q5ClK

Further company coverage: CNTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.